Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4074 |
Name | pancreatic adenocarcinoma |
Definition | A pancreatic carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Cabozantinib | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Pimasertib | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Vandetanib | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + PRI-724 | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Capecitabine + Ruxolitinib | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | CGP57380 | pancreatic adenocarcinoma | not applicable | detail... |
BRAF mutant | Trametinib | pancreatic adenocarcinoma | sensitive | detail... |
Unknown unknown | Bevacizumab + Erlotinib + Gemcitabine | pancreatic adenocarcinoma | no benefit | detail... |
Unknown unknown | GSK1904529A | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | MK2206 + Selumetinib | pancreatic adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + NSC109555 | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | BI 853520 | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Mogamulizumab + Nivolumab | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | GSK3368715 | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | GSK3203591 + GSK3368715 | pancreatic adenocarcinoma | not applicable | detail... |
Unknown unknown | Adavosertib + Gemcitabine + Radiotherapy | pancreatic adenocarcinoma | not applicable | detail... |
SMAD4 loss | Hydroxychloroquine | pancreatic adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | Everolimus + Ribociclib | pancreatic adenocarcinoma | no benefit | detail... |
Unknown unknown | Temozolomide + TRC102 | pancreatic adenocarcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602602 | Phase II | Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Gemcitabine | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Recruiting | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT01013649 | Phase II | Erlotinib + Gemcitabine Gemcitabine | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery | Active, not recruiting | USA | CAN | 2 |
NCT01088815 | Phase II | Gemcitabine + Nab-paclitaxel + Vismodegib | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | 2 |
NCT01383538 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Saridegib | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01420874 | Phase I | EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Active, not recruiting | USA | 0 |
NCT01431794 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Sonidegib | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT01473940 | Phase I | Gemcitabine + Ipilimumab | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01485744 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Sonidegib | LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01488552 | Phase Ib/II | Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01489865 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT01506973 | Phase Ib/II | Hydroxychloroquine Gemcitabine | A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT01555489 | Phase II | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | Terminated | USA | 0 | |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | CAN | 6 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 6 |
NCT01585805 | Phase II | Veliparib Cisplatin + Gemcitabine | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting | USA | CAN | 1 |
NCT01586611 | Phase III | Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer | Unknown status | CAN | 0 |
NCT01652976 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Dasatinib | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01660971 | Phase I | Dasatinib + Erlotinib + Gemcitabine | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | Active, not recruiting | USA | 0 |
NCT01666730 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Metformin | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT01683422 | Phase II | Capecitabine + Erlotinib + Gemcitabine | Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01764477 | Phase I | Gemcitabine + PRI-724 | Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT01783171 | Phase I | Dinaciclib + MK2206 | Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery | Completed | USA | CAN | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01825603 | Phase I | ADH-1 + Cisplatin + Gemcitabine | ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01858883 | Phase I | Nab-paclitaxel Filgrastim Itacitinib Gemcitabine | Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01896869 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Ipilimumab | A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT01908478 | Phase I | Veliparib Gemcitabine | A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT01921751 | Phase II | Gemcitabine + Nab-paclitaxel Capecitabine | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01924260 | Phase I | Alisertib + Gemcitabine | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT01956812 | Phase III | Yttrium Y-90 clivatuzumab tetraxetan Gemcitabine | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) | Terminated | USA | CAN | 6 |
NCT01959672 | Phase II | Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine | Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02004262 | Phase II | Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine | Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | Completed | USA | CAN | 0 |
NCT02005315 | Phase I | Gemcitabine + Nab-paclitaxel + Vantictumab | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02037230 | Phase Ib/II | Adavosertib + Gemcitabine | Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT02048384 | Phase Ib/II | Metformin + Sirolimus Metformin | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | Completed | USA | 0 |
NCT02077881 | Phase Ib/II | Indoximod Gemcitabine + Nab-paclitaxel | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02080260 | Phase II | Regorafenib | A Study of Regorafenib in Advanced Pancreatic Cancer Patients | Completed | USA | 0 |
NCT02117479 | Phase III | Ruxolitinib Capecitabine | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Terminated | USA | CAN | 10 |
NCT02119663 | Phase III | Capecitabine Capecitabine + Ruxolitinib | A Study of Ruxolitinib in Pancreatic Cancer Patients | Terminated | USA | 13 |
NCT02138383 | Phase I | Enzalutamide Nab-paclitaxel Gemcitabine | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02153450 | Phase I | Metformin | Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT02155088 | Phase I | Alpelisib + Gemcitabine + Nab-paclitaxel | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02178436 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Selinexor | Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT02184195 | Phase III | Olaparib | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO) | Active, not recruiting | USA | CAN | 10 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 3 |
NCT02194829 | Phase Ib/II | Paclitaxel Gemcitabine Adavosertib | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02227940 | Phase I | Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02231723 | Phase I | Gemcitabine + Nab-paclitaxel + Napabucasin | A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT02243371 | Phase II | GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Completed | USA | 0 |
NCT02244489 | Phase I | Capecitabine Oxaliplatin Momelotinib | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02311361 | Phase I | Durvalumab Tremelimumab | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02336087 | Phase I | Gemcitabine + Metformin + Nab-paclitaxel | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02340117 | Phase II | SGT-53 Gemcitabine + Nab-paclitaxel | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT02349867 | Phase I | Gemcitabine + Nab-paclitaxel + Sorafenib + Vorinostat | Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients | Active, not recruiting | USA | 0 |
NCT02383433 | Phase II | Gemcitabine + Regorafenib | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02399137 | Phase II | Nab-paclitaxel Gemcitabine MM-141 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | Completed | USA | CAN | 4 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02428270 | Phase II | GSK2256098 + Trametinib | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | Active, not recruiting | CAN | 0 |
NCT02436668 | Phase II | Gemcitabine + Nab-paclitaxel Ibrutinib | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma | Completed | USA | 7 |
NCT02451982 | Phase Ib/II | Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine | Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | 1 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | 1 |
NCT02562898 | Phase Ib/II | Gemcitabine + Ibrutinib + Paclitaxel | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02570711 | Phase II | Acalabrutinib Gemcitabine + Nab-paclitaxel | Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02575508 | Phase Ib/II | Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02608229 | Phase I | Gemcitabine + Nab-paclitaxel + Ulixertinib | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | 1 |
NCT02620423 | Phase I | Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab | Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Completed | USA | 0 |
NCT02620800 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + Nab-paclitaxel + Oxaliplatin | Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02620865 | Phase Ib/II | Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Active, not recruiting | USA | 0 |
NCT02648282 | Phase II | Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02650804 | Phase II | BPM 31510 BPM 31510 + Gemcitabine | BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients | Completed | USA | 1 |
NCT02651727 | Phase I | Gemcitabine + Nab-paclitaxel + VS-4718 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | Terminated | USA | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT02675946 | Phase I | CGX1321 | Study of CGX1321 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT02677038 | Phase II | Olaparib | Olaparib in Treating Patients With Stage IV Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02703571 | Phase Ib/II | Ribociclib + Trametinib | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Terminated | USA | CAN | 5 |
NCT02734160 | Phase I | Durvalumab + Galunisertib | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | Completed | USA | 4 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | 5 |
NCT02826486 | Phase II | BKT140 + Pembrolizumab BKT140 | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT) | Active, not recruiting | USA | 3 |
NCT02847000 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | Completed | USA | 0 |
NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02890355 | Phase II | Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Veliparib | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02902484 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Nintedanib Nintedanib | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT02907099 | Phase II | BKT140 + Pembrolizumab | Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Active, not recruiting | USA | 1 |
NCT02923921 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin Fluorouracil + Leucovorin + Oxaliplatin | Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer | Completed | USA | CAN | 11 |
NCT02985125 | Phase Ib/II | Everolimus + Ribociclib | LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | Active, not recruiting | USA | 0 |
NCT03006302 | Phase II | CRS-207 + Epacadostat + Pembrolizumab CRS-207 + Cyclophosphamide + Epacadostat + GVAX pancreatic cancer vaccine + Pembrolizumab | Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | Recruiting | USA | 0 |
NCT03086369 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine + Nab-paclitaxel | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 2 |
NCT03086642 | Phase I | Talimogene laherparepvec | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | Recruiting | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Recruiting | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Active, not recruiting | USA | CAN | 7 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Active, not recruiting | USA | CAN | 10 |
NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT03122106 | Phase I | Personalized cancer vaccine | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | Active, not recruiting | USA | 0 |
NCT03126435 | Phase III | EndoTAG-1 + Gemcitabine Gemcitabine | EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment | Recruiting | USA | 7 |
NCT03127124 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + NANT-008 + Oxaliplatin | QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer | Suspended | USA | 0 |
NCT03140670 | Phase II | Rucaparib | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | Active, not recruiting | USA | 0 |
NCT03153410 | Phase I | Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab | Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | Recruiting | USA | 0 |
NCT03190265 | Phase II | CRS-207 + Ipilimumab + Nivolumab CRS-207 + Cyclophosphamide + GVAX pancreatic cancer vaccine + Ipilimumab + Nivolumab | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT03192462 | Phase Ib/II | MultiTAA-specific T cells | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS) | Active, not recruiting | USA | 0 |
NCT03213626 | Phase II | Cabozantinib + Erlotinib | Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT03214250 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Nivolumab APX005M + Gemcitabine + Nab-paclitaxel APX005M + Gemcitabine + Nab-paclitaxel + Nivolumab | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03245541 | Phase Ib/II | Durvalumab | Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) | Recruiting | USA | 0 |
NCT03250273 | Phase II | Entinostat + Nivolumab | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03261947 | Phase II | TAK-931 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03269526 | Phase Ib/II | EGFRBi-armed autologous activated T cells | BATs Treatment for Pancreatic Cancer, Phase Ib/II | Recruiting | USA | 0 |
NCT03277209 | Phase I | Plerixafor | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | Terminated | USA | 1 |
NCT03281382 | Phase I | Ad5-yCD-mutTKSR39rep-hIL12 | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT03310632 | Phase Ib/II | Antroquinonol | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | Recruiting | USA | 1 |
NCT03316599 | Phase I | Ficlatuzumab + Gemcitabine + Nab-paclitaxel | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03331562 | Phase II | Pembrolizumab Paricalcitol + Pembrolizumab | A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | Completed | USA | 0 |
NCT03336216 | Phase II | Cabiralizumab + Gemcitabine + Nab-paclitaxel + Nivolumab Cabiralizumab + Nivolumab Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | Active, not recruiting | USA | CAN | 9 |
NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + MM-398 + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Recruiting | USA | 0 |
NCT03344172 | Phase II | Avelumab + Gemcitabine + Hydroxychloroquine + Nab-paclitaxel Gemcitabine + Hydroxychloroquine + Nab-paclitaxel | Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134) | Terminated | USA | 0 |
NCT03368963 | Phase Ib/II | MM-398 + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Recruiting | USA | 0 |
NCT03373188 | Phase I | Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | Recruiting | USA | 0 |
NCT03374852 | Phase II | CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | Withdrawn | 0 | |
NCT03376659 | Phase Ib/II | Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03387098 | Phase Ib/II | GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide | QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Active, not recruiting | USA | 0 |
NCT03403049 | Phase I | Cisplatin + Gemcitabine Capecitabine + Gemcitabine | Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | Completed | USA | 1 |
NCT03404960 | Phase Ib/II | Ipilimumab + Niraparib Niraparib + Nivolumab | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax) | Recruiting | USA | 0 |
NCT03410030 | Phase Ib/II | Cisplatin + Gemcitabine + Nab-paclitaxel + Vitamin C | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM) | Recruiting | USA | 0 |
NCT03432676 | Phase II | Epacadostat + Pembrolizumab | Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) | Withdrawn | 0 | |
NCT03451773 | Phase Ib/II | Gemcitabine + M7824 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | Completed | USA | 0 |
NCT03490760 | Phase II | Durvalumab | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Active, not recruiting | USA | 0 |
NCT03504423 | Phase III | CPI-613 CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas | Active, not recruiting | USA | 5 |
NCT03507452 | Phase I | BAY2287411 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | Recruiting | USA | 4 |
NCT03512756 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 Gemcitabine Fluorouracil Capecitabine | A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer | Recruiting | USA | 0 |
NCT03519308 | Phase I | Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Gemcitabine + Nab-paclitaxel + Nivolumab | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT03553004 | Phase II | Niraparib | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial | Recruiting | USA | 0 |
NCT03563144 | Phase II | Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | USA | 0 |
NCT03563248 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | Recruiting | USA | 0 |
NCT03586869 | Phase Ib/II | Aldoxorubicin + ALT-803 + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Active, not recruiting | USA | 0 |
NCT03601923 | Phase II | Niraparib | Niraparib in Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT03611556 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Oleclumab Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study | Recruiting | USA | 3 |
NCT03649321 | Phase Ib/II | Cisplatin + Gemcitabine + Nab-paclitaxel Bemcentinib + Cisplatin + Gemcitabine + Nab-paclitaxel | Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer | Recruiting | USA | 0 |
NCT03665441 | Phase III | Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1) | Active, not recruiting | USA | 2 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | USA | CAN | 2 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03697564 | FDA approved | Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine | Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). | Suspended | USA | 0 |
NCT03699319 | Phase II | CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT03723915 | Phase II | Pelareorep + Pembrolizumab | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03767582 | Phase Ib/II | BMS-813160 + GVAX pancreatic cancer vaccine + Nivolumab BMS-813160 + Nivolumab | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | Recruiting | USA | 0 |
NCT03801915 | Phase II | MVT-5873 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Recruiting | USA | 0 |
NCT03816163 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Zolbetuximab | A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 8 |
NCT03816358 | Phase Ib/II | Anetumab ravtansine + Gemcitabine + Nivolumab Anetumab ravtansine + Nivolumab Anetumab ravtansine + Ipilimumab + Nivolumab | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | Recruiting | USA | CAN | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 9 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Recruiting | CAN | 0 |
NCT03854110 | Phase Ib/II | Gemcitabine + GP-2250 GP-2250 | Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine | Recruiting | USA | 0 |
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Recruiting | USA | 0 |
NCT03891979 | FDA approved | Ciprofloxacin Metronidazole Pembrolizumab | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | Withdrawn | USA | 0 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Recruiting | USA | 5 |
NCT03956056 | Phase I | Neoantigen peptide vaccine + Poly ICLC | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | Recruiting | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03970252 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT04005690 | Phase II | Olaparib Cobimetinib | Cobimetinib or Olaparib in Treating Patients With Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04034238 | Phase I | LMB-100 + Tofacitinib | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Recruiting | USA | 0 |
NCT04050085 | Phase I | Nivolumab + SD-101 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT04058964 | Phase II | PEGPH20 + Pembrolizumab | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 1 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Recruiting | USA | 0 |
NCT04083651 | Phase II | Methylnaltrexone Bromide | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT04092673 | Phase Ib/II | eFT226 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04098081 | Phase II | Galeterone + Gemcitabine Galeterone | 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT04104672 | Phase I | AB680 + GLS-010 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | Recruiting | USA | 0 |
NCT04123574 | Phase I | Talabostat mesylate | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Recruiting | USA | 0 |
NCT04132505 | Phase I | Binimetinib + Hydroxychloroquine | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Recruiting | USA | 3 |
NCT04137536 | Phase I | EGFRBi-armed autologous activated T cells | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | Recruiting | USA | 0 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | 1 |
NCT04157127 | Phase I | DC tumor cell lysate vaccine | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (DECIST) | Recruiting | USA | 0 |
NCT04172532 | Phase Ib/II | MSC2490484A | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer | Recruiting | USA | 0 |
NCT04191421 | Phase Ib/II | Siltuximab + Spartalizumab | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT04193904 | Phase I | MRx0518 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer | Recruiting | USA | 0 |
NCT04214418 | Phase Ib/II | Atezolizumab + Cobimetinib + Hydroxychloroquine | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) | Recruiting | USA | 0 |
NCT04292743 | Phase I | Eryaspase + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT04327986 | Phase Ib/II | M7824 + NHS-IL12 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | Not yet recruiting | USA | 0 |
NCT04331041 | Phase II | Defactinib | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | Not yet recruiting | USA | 0 |
NCT04361162 | Phase II | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | Recruiting | USA | 0 |
NCT04386057 | Phase II | Hydroxychloroquine + LY3214996 LY3214996 | LY3214996 +/- HCQ in Pancreatic Cancer | Recruiting | USA | 0 |
NCT04387071 | Phase Ib/II | INCAGN01949 + QbG10 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | Not yet recruiting | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | 3 |
NCT04390763 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + NIS793 + Spartalizumab Gemcitabine + Nab-paclitaxel + NIS793 | Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | Recruiting | USA | 13 |
NCT04409002 | Phase II | Dostarlimab + Niraparib | Niraparib + Dostarlimab + RT in Pancreatic Cancer | Recruiting | USA | 0 |
NCT04543071 | Phase II | BKT140 + Cemiplimab + Gemcitabine + Nab-paclitaxel | Chemo4METPANC Combination Chemotherapy in Patients With Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT04548752 | Phase II | Olaparib + Pembrolizumab Olaparib | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | Recruiting | USA | 0 |
NCT04666740 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | Recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |